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OBJECTIVE — It is believed that disruption of vulnerable atherosclerotic plaque and subse-
quent thrombus formation play critical roles in the pathogenesis of cerebral infarction. We
simultaneously determined four relatively common genetic variants related to plaque rupture or
subsequent local thrombus formation and evaluated the combined effect on cerebral infarction.
RESEARCH DESIGN AND METHODS — We enrolled 3,094 Japanese type 2 diabetic
subjects (62.7% male; aged 61.5  8.4 years) and determined their genotypes regarding matrix
metalloproteinase 9 C-1562T, coagulation factor XII (F12) C46T, von Willebrand factor (VWF)
G-1051A,andplasminogenactivatorinhibitor(PAI-1)6754G/5Gpolymorphisms.Thediagnosisof
cerebral infarction was performed based on history, physical examination, and neuroimaging.
RESULTS — Thesingleassociationanalysisrevealedthattherewerenostatisticallysigniﬁcant
associations between each polymorphism and the prevalence of cerebral infarction. Interest-
ingly, the prevalence of cerebral infarction was higher with the increase of the total number of
four concomitant unfavorable proatherothrombotic alleles in each subject (P value for linear
trend  0.004). Furthermore, a multiple logistic regression analysis showed that the number of
proatherothrombotic alleles was a risk factor for cerebral infarction independently of conven-
tionalriskfactors(oddsratioforone-pointincreaseinthenumberofproatherothromboticallele
1.15 [95% CI 1.05–1.26], P  0.004).
CONCLUSIONS — Accumulation of gene polymorphisms related to plaque rupture and
thrombus formation is likely associated with the prevalence of cerebral infarction in type 2
diabetic patients, suggesting that the combined information about these variants is useful to
assess the risk of cerebral infarction.
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C
erebral infarction, a major cause of
severe disability and death in sub-
jects with type 2 diabetes, is caused
by focal cerebral ischemia due to arterial
occlusion. Various pathophysiological
mechanisms can result in cerebral infarc-
tion,butthemostcommononeisthrombus
formationinpreexistingatherosclerosis.Af-
ter disruption of vulnerable atherosclerotic
plaqueandexposureofprothromboticsub-
endothelial matrix, local thrombus forma-
tion occurs, which subsequently leads to
occlusion of cerebral arteries. Thus, the
pathogenesis of cerebral infarction is com-
plex and involves multiple genetic and en-
vironmentalfactorsrelatedtoatherogenesis
and thrombosis (1,2).
Severalmoleculesarereportedtoplay
key roles in the plaque rupture and sub-
sequentlocalthrombusformation.Matrix
metalloproteinase (MMP) 9 (gelatinase
B), a 92-kDa type IV collagenase, is an
enzyme with proteolytic activity against
connective tissue proteins such as collag-
ens, proteoglycans, and elastin. Since
MMP9 affects the volume expansion of
the atherosclerotic plaque, its stability,
and the potential for smooth muscle cell
proliferation by regulating connective tis-
sue remodeling, it is likely implicated in
the pathophysiology of atherogenesis and
plaque rupture, the most common mecha-
nism of atherothrombosis (3–5). Func-
tional studies indicate that the 1562CT
polymorphism has an allele-speciﬁc effect
on MMP9 transcription and that MMP9
proteinlevelsandactivitywerehigherinthe
1562T allele carriers (6,7).
Coagulation factor XII (F12; Hage-
man factor), an 80-kDa serine protease
circulating in plasma, plays a central role
in the initiation of coagulation. In some
studies, high F12a levels have been re-
ported in arterial thrombo-embolic dis-
ease (8,9). A C to T substitution at
nucleotide 46 in the 5 untranslated re-
gion of the F12 gene destroys a Kozak
consensus sequence, resulting in lower
translation efﬁciency and decreased F12a
plasma levels (10,11). von Willebrand
factor (VWF), a large circulating glyco-
protein mainly derived from vascular en-
dothelium, also plays a pivotal role in
platelet adhesion and aggregation at sites
of high shear rates such as in arteries with
stenotic or ruptured atherosclerotic
plaquelesions.ElevatedplasmaVWFlev-
els are associated with cardiovascular dis-
ease (CVD), and the plasma VWF level
has been established as an independent
predictor of cardiovascular risk (12). It
has been reported that three linked di-
morphisms (1,234C/T, 1,185A/G
and 1,051G/A) in the VWF gene pro-
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viduals with the CC/AA/GG genotype
have the highest mean VWF levels (13).
Plasminogen activator inhibitor
(PAI-1) is one of the central components
of the ﬁbrinolytic system. A deletion/
insertion (4G/5G) polymorphism at
675 bp upstream from the mRNA initi-
ation point in the promoter lesion of
PAI-1 gene is associated with plasma
PAI-1 levels. The 4G allele is associated
with higher levels of gene transcription
and elevated PAI-1 plasma levels com-
pared with 5G counterpart and thereby
possibly increases the risk for intravascu-
lar thrombosis (14).
Although there have been studies on
the associations between each polymor-
phism and CVD, such as coronary artery
disease(CAD)andcerebralinfarction,the
results of these studies remain controver-
sial (11,15–22). Since individual genetic
polymorphism generally confers only
moderate atherosclerotic risk at most, the
determination of each polymorphism
may not be enough to assess the risk of
CVD. In this study, therefore, we simul-
taneously determined four relatively
common genetic variants related to
plaque rupture or subsequent local
thrombus formation (MMP9 C-1562T,
F12 C46T, VWF G-1051A, and PAI-1
6754G/5G)andevaluatedthecombined
effect on cerebral infarction.
RESEARCH DESIGN AND
METHODS— Japanese type 2 dia-
betic subjects who periodically attended
the outpatient clinics of diabetes in ﬁve
participating hospitals (Osaka University
Medical Hospital, Ehime Prefectural Cen-
tral Hospital, Ehime Prefectural Imabari
Hospital, Ishibashi Clinic, and Naka
Kinen Clinic) during 1 year (January
2005 to December 2005) were asked to
participate in this study. We considered
subjects eligible when they had type 2 di-
abetes diagnosed by diabetologists and
were aged 40 years. The determination
of type 2 diabetes was based on World
Health Organization criteria. After all, a
total of 3,094 subjects (62.7% male,
[means  SD] aged 61.5  8.4 years, du-
ration of diabetes 8.0  7.5 years, and
A1C 7.1  1.2%) were enrolled.
The study protocol was approved by
the committees on the ethics of human
research of Osaka University Graduate
School of Medicine. A written informed
consent was obtained from all the partic-
ipantsafterafullexplanationofthestudy.
Clinical and biochemical analysis
Fasting blood samples were collected,
and A1C, serum total and HDL choles-
terol, and serum triglyceride levels were
measured using standard laboratory pro-
tocols. The determination of hyperten-
sion (deﬁned as systolic blood pressure
[SBP] 130 mmHg or diastolic blood
pressure [DBP] 80 mmHg or having
been treated for hypertension) and dys-
lipidemia (deﬁned as serum LDL choles-
terol 120 mg/dl or serum triglycerides
150 mg/dl or HDL cholesterol 40
mg/dl or having been treated for dyslipi-
demia) was based on the Japan Diabetes
Society’s criteria. Smoking status was
evaluated as follows: a value of 0 and 1
were assigned to subjects when Brink-
man’s Index (the number of cigarettes per
day times smoking years) was 200 and
200, respectively. The diagnosis of ce-
rebral infarction was performed based on
history,physicalexamination,andneuro-
imaging (computed tomography, mag-
netic resonance imaging, or both),
according to the traditional World Health
Organization criteria of stroke. The pa-
tients’ characteristics and their medica-
tion are listed in Table 1.
Genetic analysis
In the present study, four genetic poly-
morphisms that are potentially associated
with plaque disruption and/or thrombus
formation (MMP9 C-1562T, F12 C46T,
VWF G-1051A, and PAI-1 6754G/5G)
Table 1 —Patient characteristics
Sex (female/male) 1,154/1,940 (37.3/62.7)
Age (years) 61.5  8.4
Duration of diabetes (years) 8.0  7.5
Smoking status (Brinkman’s Index 200/200) 1,572/1,522 (50.8/49.2)
BMI (kg/m
2) 24.1  3.5
A1C (%) 7.1  1.2
Presence of hypertension (%) 2,352 (76.0)
SBP (mmHg) 133  18
DBP (mmHg) 80  12
Presence of dyslipidemia (%) 2,356 (76.1)
Total cholesterol (mmol/l) 4.88  0.78
HDL cholesterol (mmol/l) 1.48  0.42
Triglycerides (mmol/l) 1.41  0.98
Treatment approach for diabetes
Diet alone 541 (17.5)
Using oral hypoglycemic agent 1,793 (58.0)
Sulfonylureas 1,097 (35.5)
Thiazolidinediones 368 (11.9)
Biguanides 1,069 (34.6)
Using insulin 760 (24.6)
Treatment approach for dyslipidemia
Using statins 894 (28.9)
Using other drugs 162 (5.2)
MMP9 C-1562T polymorphism
CC genotype (%) 2,145 (69.3)
CT genotype (%) 867 (28.0)
TT genotype (%) 82 (2.7)
F12 C46T polymorphism
CC genotype (%) 386 (12.5)
CT genotype (%) 1,412 (45.6)
TT genotype (%) 1,296 (41.9)
vWF G1051A polymorphism
GG genotype (%) 985 (31.8)
GA genotype (%) 1,534 (49.6)
AA genotype (%) 575 (18.6)
PAI-1 4G/5G polymorphism
4G4G genotype (%) 1,245 (40.2)
4G5G genotype (%) 1,423 (46.0)
5G5G genotype (%) 425 (13.7)
Cerebral infarction (%) 322 (10.4)
Data are n (%) or means  SD.
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was determined to be either a proathero-
thrombotic allele or antiatherothrom-
botic allele on the basis of prior evidence
of potential functionality in plaque rup-
ture and/or thrombus formation. There-
fore, the total number of four
concomitant unfavorable proathero-
thromboticallelesineachsubjecttheoret-
ically ranges from zero (carrying no
proatherothrombotic allele) to eight (car-
rying all of the proatherothrombotic
alleles).
Venous blood was collected from
each subject and genomic DNA was iso-
lated with a DNA isolation kit (Qiagen).
The genotypes of the single nucleotide
polymorphisms (SNPs) in each subject
were determined with a ﬂuorescence- or
colorimetry-based allele-speciﬁc DNA-
primer probe assay system (Toyobo Gene
Analysis) as previously described (23).
Statistical analysis
After each polymorphism was assessed,
all the subjects were divided into two or
threegenotypegroupsbasedonthemajor
allele’s dominant (AA  Aa genotype ver-
sus aa genotype), recessive (AA genotype
versus Aa  aa genotype), and additive
genetic models (AA genotype  Aa geno-
type  aa genotype or AA genotype  Aa
genotypeaagenotype),andtheparam-
eters were compared among the groups.
Distributions of continuous variables in
groupswereexpressedasmeansSD.In
the dominant and the recessive genetic
models, data between two groups were
compared by the 
2 test or the Student’s t
test. In the additive genetic models, the
associationsbetweenpolymorphismsand
variables were evaluated with the Mantel
extension test or ANOVA with post hoc
comparison of the means. Bonferroni’s
multiple comparison procedure was ap-
plied for statistical tests to control the
family-wise type 1 error to 0.05 and
gave the corrected level of signiﬁcance,
0.0042 [  0.05/(3 	 4)], since multiple
comparisons must be performed on the
three models of four SNPs.
Multiple logistic regression analyses
were performed to evaluate the relation-
ship between the prevalence of cerebral
infarction and the following variables:
sex, age, smoking status (Brinkman’s In-
dex 200 or 200), BMI, duration of di-
abetes, A1C, prevalence of hypertension,
prevalence of dyslipidemia, and number
of proatherothrombotic alleles. For these,
thePvaluefortheinclusionandexclusion
of variables was set at 0.05.
RESULTS— Table1showsthegeneral
characteristics of the subjects. After each
of the four polymorphisms (MMP9
C-1562T, F12 C46T, VWF G-1051A, and
PAI-16754G/5G)wasassessed,wecon-
ﬁrmed that all alleles were in Hardy-
Weinberg equilibrium.
First, all subjects were divided into
two or three genotype groups based on
the major allele’s dominant, recessive,
and additive genetic models, and the pa-
rameters were compared among the
groups (supplementary Tables 1–4
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1518/DC1]). Re-
garding the PAI-1 6754G/5G polymor-
phism, the prevalence of cerebral infarc-
tion tended to be higher as the number
of proatherothrombotic alleles increased
(8.9% in the 5G/5G carriers, 9.5% in
5G/4G carriers, and 12.0% in the 4G/4G
carriers; P value for trend  0.027).
Also, the prevalence of cerebral infarc-
tiontendedtobehigherinsubjectswith
the5Gallelethanthosewithoutit(9.4%
and 12.0%, respectively, P  0.020).
However, there was no signiﬁcant asso-
ciation between this polymorphism and
the prevalence of cerebral infarction in
any genetic models after Bonferroni’s
correction was applied (supplementary
Table 1). Similarly, regarding MMP9
C-1562T, F12 C46T, and VWF G-1051A
polymorphisms, there were no statisti-
cally signiﬁcant associations between
these polymorphisms and the preva-
lenceofcerebralinfarction(supplemen-
tary Tables 2–4).
Next, the study subjects were divided
into eight groups according to the total
number of proatherothrombotic alleles
they had. The prevalence of cerebral in-
farction in the subjects with zero (n 
19), one (n  150), two (n  525), three
(n881),four(n826),ﬁve(n494),
six (n  138), and seven (n  21)
proatherothrombotic alleles were 5.3,
6.8, 9.5, 9.4, 11.5, 11.1, 15.2, and
19.0%, respectively. The proportion of
patients with cerebral infarction in-
creased progressively with increasing
number of unfavorable alleles (P value for
linear trend  0.004) (Fig. 1). Further-
more, in a multiple logistic regression
model, the number of proatherothrom-
botic alleles was signiﬁcantly associated
with cerebral infarction even after adjust-
ment for sex, age, smoking habit, BMI,
duration of diabetes, A1C, prevalence of
hypertension, and prevalence of dyslipi-
demia (odds ratio [OR] for one-point
increase in the number of proathero-
thrombotic allele 1.14 [95% CI 1.04–
1.26], P  0.006) (Table 2). The allele
riskscorewastestedforitsaccuracyinthe
predicting the prevalence of cerebral in-
farction with receiver operating curve
analysis. The area under the curve was
0.545 (95% CI 0.512–0.578) (P 
0.008). Using the median of the number
of proatherothrombotic alleles as cutoff,
patients with four or more alleles had a
signiﬁcantly increased risk of cerebral in-
farction as compared with subjects with
three or less alleles (OR 1.38 [95% CI
1.08–1.76],P0.011,bymultiplelogis-
tic regression). Using approximately the
5th and the 95th percentiles of the num-
ber of proatherothrombotic allele distri-
bution (i.e., 1 and 6, respectively), the
study population could be classiﬁed into
three subgroups: carriers of one or less
Figure 1—The prevalence of cerebral infarction in the subjects with zero to seven proathero-
thrombotic alleles. Each number of proatherothrombotic alleles is shown as a vertical bar and the
prevalenceofcerebralinfarctionisshownasdotsconnectedwithlines.Theprevalenceofcerebral
infarction tended to be greater as the number of proatherothrombotic alleles were increased. P for
trend  0.004.
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two to ﬁve unfavorable alleles (n 
2,726), and carriers of six or more unfa-
vorable alleles (n  159). The prevalence
of cerebral infarction in these three
groups increased progressively with the
increase of unfavorable allele number
(6.7, 10.4, and 15.7%, respectively, P
value for trend  0.006), while they were
similar for the other clinical and labora-
tory variables (data not shown). Consid-
ering the carriers of one or less
unfavorable allele as the reference group,
the carriers of two to ﬁve alleles tended to
have a relatively higher risk of cerebral
infarction (1.61 [0.93–2.81], P  0.092)
and the carriers of six or more alleles had
asigniﬁcantlyincreasedrisk(2.60[1.30–
5.18], P  0.007) (Fig. 2). The carriers of
six or more alleles also had a signiﬁcantly
increased risk as compared with those
with two to ﬁve alleles (1.61 [1.03–2.51],
P  0.036). Furthermore, even after ad-
justing other clinical variables, the carri-
ers of six or more alleles had a
signiﬁcantly increased risk as compared
with carriers of one or less allele (2.72
[1.30–5.69], P  0.008), although there
was no signiﬁcant difference between the
carriers of six or more alleles and the car-
riers of two to ﬁve alleles. These results
suggest that the accumulation of
proatherothrombotic alleles is associated
with the prevalence of the cerebral
infarction.
CONCLUSIONS — In the past de-
cade, numerous polymorphisms have
been reported as genetic risk factors for
CVD. However, it remained controversial
whether many of these polymorphisms
are really associated with CVD because of
their poor reproducibility. On the other
hand, there is compelling evidence that
CVD is a complex and multifactorial dis-
order and that its pathogenesis involves
multiple molecules. These ﬁndings sug-
gest that the effect of each genetic suscep-
tibilityfactorforCVDismodestbutmight
be important in the presence of other ge-
netic risk factors. These gene-gene inter-
actions might occur between different
genes whose products are part of path-
ways that ultimately lead to CVD.
It is believed that disruption of vul-
nerable atherosclerotic plaque and subse-
quent thrombus formation play critical
roles in the pathogenesis of cerebral in-
farction. In this study, we simultaneously
determined four relatively common ge-
netic variants related to plaque rupture
and/or thrombus formation (MMP9
C-1562T, F12 C46T, VWF G-1051A, and
PAI-1 6754G/5G) and evaluated their
combined effect on cerebral infarction in
Japanese type 2 diabetic patients.
First, we performed the conventional
single-association analysis, where the as-
sociation between each polymorphism
and the prevalence of cerebral infarction
was examined individually. This analysis
revealed that the prevalence of cerebral
infarction tended to be higher with the
increase of unfavorable allele number in
each polymorphism. However, in any ge-
netic models, there were no statistically
signiﬁcant associations between each
polymorphism and the prevalence of ce-
rebral infarction. Several previous case-
control studies (6,15) showed that the
MMP9 1562T allele was associated with
CAD,buttheothers,includingaprospec-
tive study and a meta-analysis (7,16),
failed to conﬁrm the association. The as-
sociation between cerebral infarction and
this polymorphism has not been evalu-
ated. Similarly, it is still controversial
whetherF12C46Tpolymorphismisasso-
Figure2—ORforcerebralinfarctioningroupsstratiﬁedonthebasisof“unfavorable”proathero-
thrombotic alleles. Using approximately the 5th and the 95th percentiles of the number of
proatherothrombotic allele distribution, the study population could be classiﬁed into three sub-
groups: carriers of one or fewer unfavorable alleles (n  209), carriers of two to ﬁve unfavorable
alleles (n  2,726), and carriers of six or more unfavorable alleles (n  159). Considering the
carriers of one or fewer unfavorable allele as the reference group, the carriers of two to ﬁve alleles
tended to have a relatively higher risk of cerebral infarction (OR 1.61 [95% CI 0.93–2.81], P 
0.092),andthecarriersofsixormorealleleshadasigniﬁcantlyincreasedrisk(2.60[1.30–5.18],
P  0.007).
Table 2—Multivariate logistic regression analysis to identify independent determinants for
cerebral infarction
OR (95%CI) P
Sex (female) 0.83 (0.59–1.17) NS
Age (years) 1.13 (1.11–1.15) 0.001
BMI (kg/m
2) 1.03 (0.99–1.07) NS
Duration of diabetes (years) 0.92 (0.90–0.95) 0.001
A1C (%) 0.90 (0.81–1.02) NS
Presence of hypertension 2.53 (1.74–3.70) 0.001
Presence of dyslipidemia 1.06 (0.79–1.43) NS
Smoking (Brinkman’s Index 200) 1.67 (1.20–2.32) 0.003
Allele risk score 1.14 (1.04–1.26) 0.006
Multivariate logistic regression analysis was done for 3,094 type 2 diabetic patients to select variables
signiﬁcantly associated with an increase in the risk of cerebral infarction. The threshold of statistical signif-
icance was deﬁned as P  0.05. NS, not signiﬁcant.
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tion-based case-control study in the
Spanish population showed that C46 al-
lelewasariskfactorforcerebralinfarction
(18), but another study in the Japanese
population failed to conﬁrm the associa-
tion (19). Regarding VWF G-1051A poly-
morphism, there have been few reports.
Although a population-based case-
controlstudyinCaucasiansindicatedthat
this polymorphism was not associated
with myocardial infarction (20), the asso-
ciation between this polymorphism and
cerebral infarction has not been evalu-
ated. Regarding PAI-1 6754G/5G poly-
morphism, several population-based
case-control studies have demonstrated
an increased risk of CAD and cerebral in-
farction in carriers of 4G allele, but these
ﬁndings have not been conﬁrmed in
largerstudies(21).Althoughrecentmeta-
analysis (22) indicated a weakly positive
associationofthe4Gallelewiththeriskof
CAD, the association between this poly-
morphism and cerebral infarction has not
been demonstrated. Thus, the results of
the previous studies were controversial
regarding the association between CVD
and each polymorphism, while most of
themwerepopulation-basedcase-control
studies and focused on CAD rather than
cerebral infarction. Taking into account
of these results and ours, it is likely that
the effect of each polymorphism is not, at
most, potent enough to deﬁnitively in-
crease the risk of cerebral infarction in in-
dividuals with and without diabetes.
Next, we assessed the combined ef-
fect of these polymorphisms on cerebral
infarction based on the working hypoth-
esis that the accumulation of these poly-
morphisms could substantially inﬂuence
the risk of atherothrombosis. We stan-
dardized the contribution of each genetic
polymorphismandusedthetotalnumber
of proatherothrombotic alleles as an index
of combined effect of these genes. Interest-
ingly, there was a statistically signiﬁcant
graded relationship between the number of
proatherothrombotic alleles and the preva-
lence of cerebral infarction (Fig. 1), and the
number of proatherothrombotic alleles was
an independent risk factor for the preva-
lence of cerebral infarction after adjusting
other clinical variables (Table 2). These re-
sults suggest that the accumulation of
proatherothrombotic alleles is associated
with the prevalence of cerebral infarction
independently of conventional risk factors.
Our study has several limitations.
First, it is sometimes difﬁcult to distin-
guish between cerebral hemorrhage and
postinfarct cerebral hemorrhage when
clinical course of the disease is unclear.
Although the subjects who had apparent
clinical course and/or the typical image
ﬁndings of postinfarct cerebral hemor-
rhage were diagnosed as having cerebral
infarction, we cannot exclude the possi-
bility that several subjects who had
postinfarct cerebral hemorrhage lesion
werefaultilycountedasoldcerebralhem-
orrhage but not as cerebral infarction.
Second, in order to avoid the type 1
error, which can be caused by multiple
comparisons, we set a strict level of the
statistical signiﬁcance. Therefore, we can-
not exclude the possibility that such strict
level of the signiﬁcance masked the weak
association between each polymorphism
and cerebral infarction.
Third, this study indicates that it is
important to examine these polymor-
phisms together with predisposition to
cerebral infarction in each individual.
However, the true mechanisms of how
the accumulation of these alleles inﬂu-
ences the development of cerebral infarc-
tion should be evaluated in further
studies.Itisalsonotedthatsincetheanal-
ysis was performed based on cross-
sectional data, a long-term follow-up
study will be required.
In addition, there was an unexpected
inverse association between the duration
of diabetes and the prevalence of cerebral
infarction in this study. One possible ex-
planation is that the duration of diabetes
in some patients did not necessarily re-
ﬂect the true duration of diabetes. There-
fore, we performed another logistic
regression analysis in which the duration
of diabetes was excluded and conﬁrmed
that the number of proatherothrombotic
alleles was still signiﬁcantly associated
with cerebral infarction (OR 1.15 [95%
CI 1.05–1.26], P  0.004) in this model
(data not shown).
In conclusion, the accumulation of
gene polymorphisms related to plaque
rupture and thrombus formation is likely
associated with the prevalence of cerebral
infarction in type 2 diabetic patients.
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